Antivascular activity of lapatinib and bevacizumab in primary microcluster cultures
Antivascular activity of lapatinib (Tykerb) and bevacizumab (Avastin) in primary microcluster cultures of breast cancer and other human neoplasms
Sub-category: New Systemic Agents - New drugs and targets (includes anti-angiogenics) - Other
Meeting: 2008 Breast Cancer Symposium
Abstract No: 166
Author(s): L. Weisenthal, D. J. Lee, N. Patel
The following tyrosine kinase inhibitors (TKI) have been shown to have antivascular (AV) activity: sunitinib (Su), sorafenib (So), gefitinib (G), erlotinib (E), and imatinib (I). To date, AV activity has not been reported for lapatinib (LAP).
We studied the ability of TKI to induce tumor cell death (TCD) and also endothelial cell death (ECD) in primary human tumor cultures, using a novel functional profiling assay system, which detects TCD vs ECD in floating cell microclusters derived with > 90% success rate from fresh human tumor biopsies (Weisenthal, 2007 ASCO GI Symposium Abst 439; [url]http://tinyurl.com/ywfnsy;[/url] Weisenthal, et al. J Intern Med, In Press).
Last edited by gdpawel : 09-11-2008 at 05:49 PM.